New Evidence Available
Updated Recommendation
A new evidence synthesis was published:2022, Updated recommendations on treatment of adolescents and children with chronic HCV infection: policy brief.
View latest version (2022)Bibliographic information
GuidelineGuidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection
Year of Publication2018
Issuing InstitutionWorld Health Organization
Recommendation
Retired
In adolescents aged 12–17 years or weighing at least 35 kg with chronic HCV, WHO recommends sofosbuvir/ribavirin for 24 weeks in genotype 3
Recommended in favor
Strong
Certainty of evidence
Very low